Tourmaline Bio Inc

TRML

Company Profile

  • Business description

    Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.

  • Contact

    27 West 24th Street
    Suite 702
    New YorkNY10010
    USA

    T: +1 646 481-9832

    https://www.tourmalinebio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    74

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,826.7048.800.56%
CAC 407,902.2523.790.30%
DAX 4024,456.8192.75-0.38%
Dow JONES (US)44,650.64192.340.43%
FTSE 1008,975.66108.641.23%
HKSE24,028.37136.050.57%
NASDAQ20,630.6619.330.09%
Nikkei 22539,646.36174.92-0.44%
NZX 50 Index12,760.208.41-0.07%
S&P 5006,280.4617.200.27%
S&P/ASX 2008,589.2050.600.59%
SSE Composite Index3,509.6816.630.48%

Market Movers